METHODS FOR EVALUATING ANGIOGENIC POTENTIAL IN CULTURE
The present invention provides a method of evaluating the angiogenic potential of a tumor, and for predicting the efficacy of anti-angiogenic therapies on an individualized basis. The method of the invention involves preparing an angiogenic signature for malignant cells in culture by assaying for the presence or level of one or more angiogenesis-related factors selected from VEGF/VPF, IL8/CXCL8, TGF-β1, TGF-β2, TGF-β3, bFGF/FGF-2, EGF, PDGF-AA, PDGF-AA/BB, IP-10, and Flt-3 ligand. The angiogenic signature may be prepared from cultures maintained under normoxic and/or hypoxic environments. The invention may be used in conjunction with chemoresponse testing of anti-tumor agents, to predict or suggest a combination therapy for cancer patients.
1 . A method for creating an angiogenic signature for a tumor specimen, comprising: culturing malignant cells from a patient tumor specimen; and testing the cell culture for the presence and/or levels of at least three angiogenesis- related factors selected from VEGF/VPF, bFGF/FGF-2, IL-8/CXCL8, EGF, Flt-3 ligand, PDGF-AA, PDGF-AA/BB, IP-10/CXCL10, TGF-β1, TGF-β2, and TGF-β3.
2 . The method of claim 1 , wherein the cell culture is maintained under normoxic conditions.
3 . The method of claim 1 , wherein cell cultures are maintained in hypoxic and normoxic environments in sequence or in parallel, and the presence and/or levels of the angiogenesis-related factors are tested in both.
4 . The method of claim 1 , wherein at least five of VEGF, PDGF-AA, PDGF-AA/BB, IL-8, bFGF/FGF-2, EGF, IP-10/CXCL10, Flt-3 ligand, TGF-β1, TGF-β2, and TGF-β3 are tested.
5 . The method of claim 1 , wherein all of VEGF, PDGF-AA, PDGF-AA/BB, IL-8, bFGF/FGF-2, EGF, IP-10/CXCL10, Flt-3 ligand, TGF-β1, TGF-β2, and TGF-β3 are tested.
6 . The method of claim 1 , wherein the tumor specimen is a breast or lung cancer.
7 . The method of claim 1 , wherein the cell culture is enriched for malignant cells.
8 . The method of claim 7 , wherein the malignant cells are cultured from cohesive multicellular particulates of the patient tumor specimen.
9 . The method of claim 1 , wherein the cells from the cell culture are further exposed to chemotherapeutic agents for chemoresponse testing.
10 . A method for preparing a predictive model for predicting efficacy of angiogenic therapy, comprising:
culturing malignant cells from a plurality of patient tumor specimens;
preparing an angiogenic signature for each tumor specimen by testing each cell culture for the presence and/or level of at least three angiogenesis-related factors selected from VEGF/VPF, bFGF/FGF-2, IL-8/CXCL8, EGF, Flt-3 ligand, PDGF-AA, PDGF-AA/BB, IP-10/CXCL10, TGF-β1, TGF-β2, and TGF-β3; and
matching the angiogenic signatures with treatment regimens and clinical outcomes for said patients, to thereby prepare a predictive model.
11 . The method of claim 10 , wherein the cell culture is maintained under normoxic conditions.
12 . The method of claim 10 , wherein cultures are maintained in hypoxic and normoxic environments in sequence or in parallel, and the presence and/or levels of the angiogenesis-related factors are tested in both.
13 . The method of claim 10 , wherein the angiogenic signature comprises the test results for at least five of VEGF, PDGF-AA, PDGF-AA/BB, IL-8, bFGF/FGF-2, EGF, IP-10/CXCL10, Flt-3 ligand, TGF-β1, TGF-β2, and TGF-β3.
14 . The method of claim 10 , wherein the aniogenic signature comprises the test results for all of VEGF, PDGF-AA, PDGF-AA/BB, IL-8, bFGF/FGF-2, EGF, IP-10/CXCL10, Flt-3 ligand, TGF-β1, TGF-β2, and TGF-β3.
15 . The method of claim 10 , wherein the tumor specimens are breast and/or lung cancer specimens.
16 . The method of claim 10 , wherein the cell cultures are enriched for malignant cells.
17 . The method of claim 16 , wherein the malignant cells are cultured from cohesive multicellular particulates of a patient tumor specimen.
18 . The method of claim 10 , wherein the patient treatment regimens include treatment with bevacizumab.
19 . The method of claim 10 , wherein the patient outcomes include resistance or development of resistance to said anti-angiogenic treatment.
20 . A method for predicting efficacy of an anti-angiogenic treatment, comprising:
culturing malignant cells from a patient tumor specimen;
preparing an angiogenic signature for the tumor specimen by testing the cell culture for the presence and/or levels of at least three angiogenesis-related factors selected from VEGF/VPF, bFGF/FGF-2, IL-8/CXCL8, EGF, Flt-3 ligand, PDGF-AA, PDGF-AA/BB, IP-10/CXCL10, TGF-β1, TGF-β2, and TGF-β3; and
matching the angiogenic signature with a model signature correlated to angiogenic treatment regimen and patient outcome.
21 . The method of claim 20 , wherein the cell culture is maintained under normoxic conditions.
22 . The method of claim 20 , wherein cultures are maintained in hypoxic and normoxic environments in sequence or in parallel, and the presence and/or levels of the angiogenesis-related factors are tested in both.
23 . The method of claim 20 , wherein at least five of VEGF, PDGF-AA, PDGF-AA/BB, IL-8, bFGF/FGF-2, EGF, IP-10/CXCL10, Flt-3 ligand, TGF-[beta]1, TGF-[beta]2, and TGF-[beta]3 are tested.
24 . The method of claim 20 , wherein all of VEGF, PDGF-AA, PDGF- AA/BB, IL-8, bFGF/FGF-2, EGF, IP-10/CXCL10, Flt-3 ligand, TGF-[beta]1, TGF-[beta]2, and TGF-[beta]3 are tested.
25 . The method of claim 20 , wherein the tumor specimen is a breast or lung cancer.
26 . The method of claim 20 , wherein the cell culture is enriched for malignant cells.
27 . The method of claim 26 , wherein the malignant cells are cultured from cohesive multicellular particulates of a patient tumor specimen.
28 . The method of claim 20 , wherein the cells from the cell culture are exposed to chemotherapeutic agents for chemoresponse testing.